Search Result

Results for "

HCV+replicon

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CHIKV (4) Drug Metabolite (4) Endogenous Metabolite (4) Enterovirus (4) HBV (2) HCV (31) HCV Protease (3) IFNAR (1) Influenza Virus (1) Isotope-Labeled Compounds (10) JAK (1) Reference Standards (3) SARS-CoV (7) STAT (1) Topoisomerase (4)
By Research Areas:	Cancer (6) Infection (33) Inflammation/Immunology (8)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W063968

RO8191 20+ Cited Publications CDM-3008; RO4948191	IFNAR JAK STAT HCV HBV	Infection
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC₅₀ of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .

HY-12530

Velpatasvir 5+ Cited Publications GS-5816	HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-10466

Daclatasvir Maximum Cited Publications 47 Publications Verification BMS-790052; EBP 883	HCV	Infection
Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for *multiple HCV replicon* genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀**s of 1.5 µM and 3.27 µM, respectively .

HY-125371

2'-C-Methyladenosine 2 Publications Verification	HCV	Infection Inflammation/Immunology
2'-C-Methyladenosine is an inhibitor of hepatitis C virus (HCV) replication. 2'-C-Methyladenosine inhibits HCV replicon and NS5B-catalyzed RNA synthesis with IC₅₀ values of 0.3μM and 1.9 μM, respectively. 2'-C-Methyladenosine also potently inhibits LRV1 in Leishmania guyanensis (Lgy) and Leishmania braziliensis .

HY-10465

Daclatasvir dihydrochloride Maximum Cited Publications 47 Publications Verification BMS-790052 dihydrochloride; EBP 883 dihydrochloride	HCV	Infection
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for *multiple HCV replicon* genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀**s of 1.5 μM and 3.27 μM, respectively .

HY-109035

Inarigivir soproxil 1 Publications Verification SB9200; GS-9992	HCV HBV	Infection
Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC₅₀s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .

HY-101662

Pibrentasvir ABT-530	HCV	Infection
Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC₅₀s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

HY-15236

PSI-6206 3 Publications Verification RO 2433; GS-331007	HCV	Infection
PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits *HCV replicon* with EC₉₀ of >100 μM.

HY-15005S1

Sofosbuvir-d6 1 Publications Verification PSI-7977-d₆; GS-7977-d₆	Isotope-Labeled Compounds HCV	Infection
Sofosbuvir-d₆ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-135867E

NHC-triphosphate tetraammonium 5+ Cited Publications	CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-triphosphate tetraammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetraammonium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-N0620

Mulberroside C 1 Publications Verification	HCV	Infection
Mulberroside C is one of the main bioactive constituents in mulberry (Morus alba L.) . Mulberroside C is a *HCV replicon* inhibitor. Antiviral activity .

HY-138305

HCV-IN-31	HCV	Infection Inflammation/Immunology
HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC₅₀/EC₉₅ of 15.7 μM for HCV replicon .

HY-135867

NHC-triphosphate	CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-12530R

Velpatasvir (Standard) GS-5816 (Standard)	Reference Standards HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-10465R

Daclatasvir dihydrochloride (Standard) BMS-790052 dihydrochloride (Standard); EBP 883 dihydrochloride (Standard)	Reference Standards HCV	Infection
Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for *multiple HCV replicon* genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀**s of 1.5 µM and 3.27 µM, respectively .

HY-15005A

PSI-7976	HCV	Infection
PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-135867A

NHC-triphosphate tetrasodium	CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase	Infection
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-15005B

Sofosbuvir impurity C	Drug Metabolite	Others
Sofosbuvir impurity C is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15005S

Sofosbuvir-13C,d3 PSI-7977-¹³C,d₃; GS-7977-¹³C,d₃	Isotope-Labeled Compounds HCV	Infection
Sofosbuvir- ¹³C,d₃ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-112047

GSK8175 GSK2878175	HCV	Infection
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .

HY-135867F

NHC-diphosphate triammonium 1 Publications Verification	CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-15236S

PSI-6206-13C,d3 RO-2433-¹³C,d₃; GS-331007-¹³C,d₃; Sofosbuvir metabolite GS-331007-¹³C,d₃	HCV	Infection
PSI-6206- ¹³C,d₃ is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

HY-12530S1

Velpatasvir-d3 GS-5816-d3₃	Isotope-Labeled Compounds SARS-CoV HCV	Infection Inflammation/Immunology Cancer
Velpatasvir-d₃ (GS-5816-d₃) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-131905S

BMS-986144	Isotope-Labeled Compounds HCV Protease HCV	Infection Inflammation/Immunology Cancer
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC₅₀s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .

HY-I0719

Sofosbuvir impurity B	Drug Metabolite	Others
Sofosbuvir impurity B is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-I0723

Sofosbuvir impurity D	Drug Metabolite	Others
Sofosbuvir impurity D is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-I0727

Sofosbuvir impurity E	Drug Metabolite	Others
Sofosbuvir impurity E is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-12373

AV-4025 hydrochloride	HCV Protease Influenza Virus	Infection
AV-4025 hydrochloride (Compound 13a) is an orally active NS5A inhibitor. AV-4025 hydrochloride is active against the HCV replicon GT1b (EC₅₀ = 0.003 nM). AV-4025 hydrochloride can be used for research on hepatitis C infection .

HY-19921

JTK-853	HCV	Infection
JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in *HCV replicon* cells with EC₅₀s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.

HY-10466S

Daclatasvir-d6 BMS-790052-d₆; EBP 883-d₆	Isotope-Labeled Compounds HCV	Infection
Daclatasvir-d₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-10466S2

Daclatasvir-d16 BMS-790052-d₁₆; EBP 883-d₁₆	Isotope-Labeled Compounds HCV	Infection
Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-10466R

Daclatasvir (Standard) BMS-790052 (Standard); EBP 883 (Standard)	Reference Standards HCV	Infection
Daclatasvir (Standard) is the analytical standard of Daclatasvir. This product is intended for research and analytical applications. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .

HY-W749691

(S)-Velpatasvir-13c,d3 (S)-GS-5816-¹³C,d₃	Isotope-Labeled Compounds SARS-CoV HCV	Infection Inflammation/Immunology Cancer
(S)-Velpatasvir- ¹³C,d₃ ((S)-GS-5816- ¹³C,d₃) is ¹³C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM ^.

HY-12530S3

Velpatasvir-13C,d3 GS-5816-¹³C,d₃	Isotope-Labeled Compounds	Infection Inflammation/Immunology Cancer
Velpatasvir- ¹³C,d₃ (GS-5816- ¹³C,d₃) is ¹³C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-15236S1

PSI-6206-d1,13C,15N2 RO 2433--d¹,¹³C,¹⁵N₂; GS-331007--d¹,¹³C,¹⁵N₂	HCV Isotope-Labeled Compounds	Infection
PSI-6206-d1, ¹³C, ¹⁵N₂ is ¹⁵N and ¹³C labeled PSI-6206 (HY-15236). PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits *HCV replicon* with EC₉₀ of >100 μM.

HY-10466S1

Daclatasvir-13C2,d6 BMS-790052-¹³C₂,d₆; EBP 883-¹³C₂,d₆	Isotope-Labeled Compounds HCV	Infection
Daclatasvir- ¹³C2,d₆ (BMS-790052- ¹³C2,d₆) is ¹³C and deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for *multiple HCV replicon* genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀**s of 1.5 μM and 3.27 μM, respectively .

HY-108029

Deldeprevir sodium ACH-2684 sodium; Neceprevir sodium	HCV HCV Protease	Infection
Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0620

Mulberroside C 1 Publications Verification	Infection Monophenols other families Classification of Application Fields Phenols Plants Moraceae Disease Research Fields Source Classification Morus alba Linn.	HCV
Mulberroside C is one of the main bioactive constituents in mulberry (Morus alba L.) . Mulberroside C is a *HCV replicon* inhibitor. Antiviral activity .

HY-135867

NHC-triphosphate	Infection Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867A

NHC-triphosphate tetrasodium	Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867F

NHC-diphosphate triammonium 1 Publications Verification	Infection Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	CHIKV Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

Cat. No.	Product Name	Chemical Structure

HY-15005S1

Sofosbuvir-d6 1 Publications Verification
Sofosbuvir-d₆ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15005S

Sofosbuvir-13C,d3
Sofosbuvir- ¹³C,d₃ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15236S

PSI-6206-13C,d3
PSI-6206- ¹³C,d₃ is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

HY-12530S1

Velpatasvir-d3
Velpatasvir-d₃ (GS-5816-d₃) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-131905S

BMS-986144
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC₅₀s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .

HY-10466S

Daclatasvir-d6
Daclatasvir-d₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-10466S2

Daclatasvir-d16
Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-W749691

(S)-Velpatasvir-13c,d3
(S)-Velpatasvir- ¹³C,d₃ ((S)-GS-5816- ¹³C,d₃) is ¹³C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM ^.

HY-12530S3

Velpatasvir-13C,d3
Velpatasvir- ¹³C,d₃ (GS-5816- ¹³C,d₃) is ¹³C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-15236S1

PSI-6206-d1,13C,15N2
PSI-6206-d1, ¹³C, ¹⁵N₂ is ¹⁵N and ¹³C labeled PSI-6206 (HY-15236). PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits *HCV replicon* with EC₉₀ of >100 μM.

HY-10466S1

Daclatasvir-13C2,d6

Daclatasvir- ¹³C2,d₆ (BMS-790052- ¹³C2,d₆) is ¹³C and deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HCV+replicon

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products